EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information Apr 19, 2018 07:00AM
EyePoint Pharma (EYPT) Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU Apr 12, 2018 07:04AM
EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™ Apr 12, 2018 07:00AM
pSivida (PSDV) Announces Acquisition of Icon Bioscience Mar 28, 2018 04:11PM
pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners – Company Will Rebrand as EyePoint Pharmaceuticals, I Mar 28, 2018 04:05PM
View Older Stories

Mar 19, 2018 12:36PM pSivida (PSDV) Announces FDA Acceptance For Filing of NDA for Durasert Three-Year Treatment for Posterior Segment Uveitis
Mar 19, 2018 12:35PM pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis
Mar 5, 2018 08:00AM pSivida To Present at the 30th Annual ROTH Conference
Feb 9, 2018 07:00AM pSivida to Present at the 2018 BIO CEO & Investor Conference
Feb 7, 2018 04:44PM pSivida (PSDV) Says Second Phase 3 Study for Durasert Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy, Safety Profile at 12 Months
Feb 7, 2018 04:02PM pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
Feb 7, 2018 04:01PM pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months
Jan 24, 2018 07:00AM pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Jan 8, 2018 08:30AM pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
Jan 4, 2018 07:14AM pSivida (PSDV) Secures Waiver from FDA for New Drug Application Filing Fee
Jan 4, 2018 07:00AM pSivida Granted Waiver by the FDA for New Drug Application Filing Fee
Jan 2, 2018 04:01PM pSivida to Present at the Annual Biotech Showcase Conference
Dec 14, 2017 07:00AM HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
Nov 7, 2017 06:00AM pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
Oct 18, 2017 07:00AM pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Oct 10, 2017 07:05AM pSivida (PSDV) Announces Strategic Collaboration Agreement with Nicox SA to Develop Sustained Release Drug to Lower Intraocular Pressure
Oct 10, 2017 07:00AM pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
Oct 10, 2017 01:31AM Nicox and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma
Sep 26, 2017 07:00AM pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs
Sep 22, 2017 02:29PM pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Sep 11, 2017 04:01PM pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
Sep 11, 2017 07:00AM pSivida to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 5, 2017 07:00AM pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th
Aug 1, 2017 07:00AM pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017
Jul 18, 2017 07:00AM Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
Jul 10, 2017 04:10PM pSivida (PSDV) Out-licenses EMEA Rights for Durasert While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera (ALIM) for ILUVIEN Improves pSivida's Revenue Generatio
Jul 10, 2017 04:01PM pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUV
Jun 28, 2017 07:00AM pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
Jun 22, 2017 07:02AM pSivida (PSDV) Submits MAA for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in EU
Jun 22, 2017 07:00AM pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union
Jun 13, 2017 07:03AM pSivida's (PSDV) Three-year Treatment for Posterior Segment Uveitis Achieves Primary Efficacy Endpoint in Second Phase 3 Study
Jun 13, 2017 07:00AM pSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
May 8, 2017 09:17AM pSivida (PSDV) Announces Positive Durasert 3-Year Treatment Data
May 8, 2017 09:15AM Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
May 4, 2017 04:01PM pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track
Apr 19, 2017 04:01PM pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th
Mar 15, 2017 07:11AM pSivida (PSDV) Says Abstract on Treatment of Posterior Segment Uveitis Accepted for Presentation at ARVO
Mar 15, 2017 07:00AM Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Feb 10, 2017 07:00AM pSivida to Present at the 2017 BIO CEO & Investor Conference
Feb 7, 2017 04:01PM pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results
Jan 25, 2017 07:00AM pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
Nov 7, 2016 04:15PM Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development
Nov 7, 2016 04:01PM pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline
Oct 31, 2016 07:00AM pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
Oct 4, 2016 07:04AM pSivida (PSDV) Completes Enrollment of Second Medidur Phase 3
Oct 4, 2016 07:00AM Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target
Sep 27, 2016 07:08AM pSivida (PSDV) Appoints New Director
Sep 27, 2016 07:00AM pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist
Sep 22, 2016 09:00AM pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference
Sep 20, 2016 04:01PM pSivida Reports Inducement Awards to New President and Chief Executive Officer
View Older Stories